Cargando…

Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial

BACKGROUND: Acute exacerbation (AE) in idiopathic pulmonary fibrosis and other idiopathic interstitial pneumonias (IIPs) are poor prognostic events although they are usually treated with conventional therapy with corticosteroids and immunosuppressants. Previously, we demonstrated the safety and effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arai, Toru, Kida, Hiroshi, Ogata, Yoshitaka, Marumo, Satoshi, Matsuoka, Hiroto, Gohma, Iwao, Yamamoto, Suguru, Mori, Masahide, Sugimoto, Chikatoshi, Tachibana, Kazunobu, Akira, Masanori, Inoue, Yoshikazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Interstitial Lung Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239513/ https://www.ncbi.nlm.nih.gov/pubmed/32423894 http://dx.doi.org/10.1136/bmjresp-2020-000558

Ejemplares similares

Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin
por: Arai, Toru, et al.
Publicado: (2021)

Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases
por: Swigris, Jeffrey J, et al.
Publicado: (2022)

Analytic Morphomics in Myositis-Related Interstitial Lung Disease
por: O’Mahony, Alexander T., et al.
Publicado: (2023)

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
por: Wild, Jim M, et al.
Publicado: (2021)

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
por: Flaherty, Kevin R, et al.
Publicado: (2017)

Feasibility of cardiopulmonary exercise testing in interstitial lung disease: the PETFIB study
por: Tomlinson, Owen, et al.
Publicado: (2021)

Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases
por: Salonen, Johanna, et al.
Publicado: (2020)

Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians
por: Althobiani, Malik, et al.
Publicado: (2021)

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review
por: Shah Gupta, Rikisha, et al.
Publicado: (2023)

Predictors of postoperative acute exacerbation of interstitial lung disease: a case–control study
por: Hosoki, Keisuke, et al.
Publicado: (2020)

Diagnoses and treatments for participants with interstitial lung abnormalities detected in the Yorkshire Lung Screening Trial
por: Upperton, Sara, et al.
Publicado: (2023)

The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019)

Patient perspectives on home-spirometry in interstitial lung disease: a qualitative co-designed study
por: Mandizha, Jessica, et al.
Publicado: (2023)

Defining the pathway to timely diagnosis and treatment of interstitial lung disease: a US Delphi survey
por: Case, Amy Hajari, et al.
Publicado: (2023)

Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses
por: Fields, Aislin, et al.
Publicado: (2023)

Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study
por: Troy, Lauren K, et al.
Publicado: (2019)

CD4+T cells in ageing-associated interstitial lung abnormalities show evidence of pro-inflammatory phenotypic and functional profile
por: Machahua, Carlos, et al.
Publicado: (2021)

Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis
por: Nayebirad, Sepehr, et al.
Publicado: (2023)

Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy
por: Sgalla, Giacomo, et al.
Publicado: (2015)

Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis
por: Aoshima, Yoichiro, et al.
Publicado: (2021)

In vivo polarisation sensitive optical coherence tomography for fibrosis assessment in interstitial lung disease: a prospective, exploratory, observational study
por: Vaselli, Margherita, et al.
Publicado: (2023)

Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study
por: Lang, David, et al.
Publicado: (2021)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
por: Saketkoo, Lesley Ann, et al.
Publicado: (2014)

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
por: Maher, Toby M, et al.
Publicado: (2018)

Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs
por: Barratt, Shaney L, et al.
Publicado: (2018)

Reliability and responsiveness of the D12 and validity of its scores as a measure of dyspnoea severity in patients with rheumatoid arthritis-related interstitial lung disease
por: Swigris, Jeffrey J, et al.
Publicado: (2023)

Combined pulmonary fibrosis and emphysema: effect of pulmonary rehabilitation in comparison with chronic obstructive pulmonary disease
por: Tomioka, Hiromi, et al.
Publicado: (2016)

Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services
por: Barratt, Shaney L, et al.
Publicado: (2021)

Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry
por: Tsubouchi, Kazuya, et al.
Publicado: (2023)

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
por: Corte, Tamera J, et al.
Publicado: (2021)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2019)

Early Intervention Can Improve Clinical Outcome of Acute Interstitial Pneumonia
por: Suh, Gee Young, et al.
Publicado: (2006)

Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis
por: McGrath, Emmet E, et al.
Publicado: (2012)

A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis
por: Belkin, Amanda, et al.
Publicado: (2014)

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2014)

Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA)
por: Yorke, Janelle, et al.
Publicado: (2014)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations
por: Coghlan, Meghan A, et al.
Publicado: (2014)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f8tifq62mnfjen8mhu2qjbl2lk